{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:21:52Z","timestamp":1791685312101,"version":"4.3.4"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Pharmacologic blockade of neurohormonal pathways in patients with acute myocardial infarction (MI) can result in acute changes in biomarkers of kidney function. We evaluated the effect of sacubitril\/valsartan versus ramipril on initial changes in serum creatinine and the association of these changes with longer-term outcomes among participants in PARADISE-MI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this randomized, double-blind, active-controlled, event-driven trial, 5661 patients with an acute MI were assigned to receive sacubitril\/valsartan or ramipril, with no run-in. The frequency of an initial pre-specified increase in serum creatinine (\u226526.5 or \u226544\u2009\u03bcmol\/L) from baseline to week 1 was compared between arms. Multivariable Cox regression models were fit to examine the association of acute changes in serum creatinine with the primary cardiovascular composite outcome (cardiovascular death, first heart failure hospitalization, or outpatient heart failure), all-cause mortality, and longer-term changes in estimated glomerular filtration rate (eGFR). An initial increase in serum creatinine \u226526.5\u2009\u03bcmol\/L occurred in 155 of 2604 (6.0%) patients assigned to sacubitril\/valsartan and 120 of 2603 (4.6%) patients assigned to ramipril (odds ratio [OR] 1.32; 95% confidence interval [CI] 1.03\u20131.68). The corresponding numbers for an increase \u226544\u2009\u03bcmol\/L were 57 (2.2%) and 42 (1.6%), respectively (OR 1.37; 95% CI 0.92\u20132.05). A higher odds of increased serum creatinine \u226526.5 and \u226544\u2009\u03bcmol\/L for sacubitril\/valsartan versus ramipril appeared to be restricted to patients who had a greater decline in systolic blood pressure over the same period (p-interaction\u2009=\u20090.05 and 0.001, respectively). In multivariable analyses, neither an acute increase in serum creatinine \u226526.5 or \u226544\u2009\u03bcmol\/L was associated with a higher risk of cardiovascular outcomes, all-cause mortality, or differences in longer-term eGFR slope. Findings were similar across the randomized treatment arms (p-interaction &amp;gt;0.6 for all).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Following acute MI, patients assigned to sacubitril\/valsartan had a higher frequency of initial increases in serum creatinine at 1\u2009week, compared with ramipril. In adjusted models, initial increases in serum creatinine with either treatment were not associated with adverse cardiovascular outcomes or changes in longer-term kidney function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3386","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T07:06:50Z","timestamp":1721977610000},"page":"1984-1992","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Acute Changes in Kidney Function and Outcomes Following an Acute Myocardial Infarction: Insights from PARADISE-MI"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-0533","authenticated-orcid":false,"given":"Finnian R.","family":"Mc Causland","sequence":"first","affiliation":[{"name":"Renal Division, Department of Medicine, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina M.","family":"McGrath","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Medicine, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Barkoudah","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Department of Medicine, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"East","sequence":"additional","affiliation":[{"name":"Baylor Soltero CV Research Center, Baylor Scott and White Heart and Vascular Hospital , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Cardiology Service, Sanatorio Modelo Quilmes , Quilmes ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karola S.","family":"Jering","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldrin F.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University , Palo Alto, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freny Vaghaiwalla","family":"Mody","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at University of California Los Angeles and Division of Cardiology, Veterans Affairs Greater Los Angeles Health Care System , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Tokmakova","sequence":"additional","affiliation":[{"name":"University Multiprofile Hospital for Active Treatment Sv. Georgi, Medical University Plovdiv , Plovdiv ,","place":["Bulgaria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation , East Hanover, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"2026010913051407600_ejhf3386-bib-0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1161\/CIRCULATIONAHA.111.039909","article-title":"Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: A report from the national cardiovascular data registry","volume":"125","author":"Fox","year":"2012","journal-title":"Circulation"},{"key":"2026010913051407600_ejhf3386-bib-0002","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/CCM.0b013e3181b9eb3b","article-title":"Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission","volume":"38","author":"Marenzi","year":"2010","journal-title":"Crit Care Med"},{"key":"2026010913051407600_ejhf3386-bib-0003","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archinte.168.9.987","article-title":"Long-term prognosis of acute kidney injury after acute myocardial infarction","volume":"168","author":"Parikh","year":"2008","journal-title":"Arch Intern Med"},{"key":"2026010913051407600_ejhf3386-bib-0004","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1681\/ASN.2006010063","article-title":"Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction","volume":"17","author":"Jose","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026010913051407600_ejhf3386-bib-0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2026010913051407600_ejhf3386-bib-0006","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2026010913051407600_ejhf3386-bib-0007","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJM199209033271002","article-title":"Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)","volume":"327","author":"Swedberg","year":"1992","journal-title":"N Engl J Med"},{"key":"2026010913051407600_ejhf3386-bib-0008","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ejhf.2421","article-title":"Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure","volume":"24","author":"Mc Causland","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913051407600_ejhf3386-bib-0009","volume-title":"Clinical study transparency: Clinical study registration, results reporting and data sharing","author":"Novartis Public Affairs"},{"key":"2026010913051407600_ejhf3386-bib-0010","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and baseline characteristics","volume":"23","author":"Jering","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913051407600_ejhf3386-bib-0011","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913051407600_ejhf3386-bib-0012","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ehjqcco\/qcx020","article-title":"Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction","volume":"4","author":"Mody","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026010913051407600_ejhf3386-bib-0013","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1681\/ASN.V12102051","article-title":"Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone","volume":"12","author":"Taal","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2026010913051407600_ejhf3386-bib-0014","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913051407600_ejhf3386-bib-0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026010913051407600_ejhf3386-bib-0016","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/9\/1984\/65511167\/eurjhf_26_9_1984.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/9\/1984\/65511167\/eurjhf_26_9_1984.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:06:04Z","timestamp":1767981964000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/9\/1984\/8328667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,26]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3386","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"2024-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}